Related Experiment Video

Updated: Aug 10, 2026

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE
09:24

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE

Published on: April 15, 2014

Prostaglandin production in chronic progressive multiple sclerosis

J A Aberg1, L M Demers, P J Romano

  • 1Department of Pathology, Penn State College of Medicine, Hershey, Pennsylvania 17033.

Journal of Clinical Laboratory Analysis
|January 1, 1990
PubMed

Insights

Peripheral blood monocytes from patients with chronic progressive multiple sclerosis (MS) produce significantly more prostaglandin E2 (PGE2) than those from healthy individuals or patients with other MS forms. Thromboxane B2 (TxB2) levels did not differ significantly between groups.

Area of Science:

  • Immunology
  • Neuroscience
  • Biochemistry

Background:

  • Peripheral blood monocytes play a role in the immune responses associated with multiple sclerosis (MS).
  • Understanding monocyte-derived inflammatory mediators is crucial for MS research.

Purpose of the Study:

  • To investigate prostaglandin E2 (PGE2) and thromboxane B2 (TxB2) release from monocytes in multiple sclerosis (MS) patients.
  • To compare mediator production between different MS subtypes and healthy controls.

Main Methods:

  • Peripheral blood monocytes were isolated from patients with chronic progressive MS, exacerbation/remitting MS, and healthy controls.
  • Monocytes were exposed to complement in vitro.
  • Prostaglandin E2 (PGE2) and thromboxane B2 (TxB2) levels in the supernatant were measured.

Main Results:

  • Monocytes from patients with chronic progressive MS exhibited significantly higher prostaglandin E2 (PGE2) production compared to healthy controls and patients with other MS forms.
  • No significant differences in thromboxane B2 (TxB2) release were observed between the groups.

Conclusions:

  • Elevated PGE2 production by monocytes may be a characteristic feature of chronic progressive multiple sclerosis.
  • These findings suggest a potential role for PGE2 in the immunopathology of progressive MS.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis05:44

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...